University of Florida, Gainesville, FL.
Maitland, FL.
J Am Vet Med Assoc. 2023 Mar 25;261(S1):S36-S47. doi: 10.2460/javma.22.12.0570. Print 2023 Jun 1.
Oclacitinib was approved in the United States 10 years ago for the management of atopic dermatitis (AD) and allergic skin disease in dogs. Many studies and case reports have been published in the past 10 years on the efficacy and safety of this medication, both at labeled doses to treat allergic dogs and off label to treat other diseases and given to other species. Concerns and confusion have occurred for both clinicians and owners regarding the long-term safety of this drug. The purpose of this review is to present the current knowledge on the efficacy, speed of action, effects on the immune system, and clinical safety of oclacitinib, based on evidence and published literature. We also aim to summarize the lessons learned in the past 10 years and to propose directions for the future.
奥卡替尼 10 年前在美国获得批准，用于治疗犬类特应性皮炎（AD）和过敏性皮肤病。在过去的 10 年中，许多关于这种药物疗效和安全性的研究和病例报告已经发表，包括在标签剂量下治疗过敏性犬和标签外治疗其他疾病以及用于其他物种。临床医生和犬主都对这种药物的长期安全性表示担忧和困惑。本综述的目的是基于证据和已发表的文献，介绍奥卡替尼的疗效、作用速度、对免疫系统的影响和临床安全性的最新知识。我们还旨在总结过去 10 年的经验教训，并为未来提出方向。
